Benzinga's Top #PreMarket Gainers

shares gained 11.13% to $52.10 in the pre-market trading session after the company reported stronger-than-expected earnings for the fourth quarter.

shares surged 7.04% to $1,202.00 in pre-market trading after the company reported stronger-than-expected results for the fourth quarter results.

gained 6.59% to $2.91 in pre-market trading after the company announced the acceptance of New Drug Application for cobimetinib in combination with vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.

shares rose 5.79% to $48.99 in pre-market trading after the company reported a narrower-than-expected Q4 loss.

shares climbed 4.12% to $52.80 in pre-market trading after dropping 10.74% on Wednesday.